Next Article in Journal
4-Amino-2-butyl-7-methoxycarbonylthiazolo[4,5-c]quinoline
Previous Article in Journal
An Efficient Synthesis of Novel 3-[(Heteroaryl-2-ylimino)-methyl]-4-hydroxy-chromen-2-ones and Analogue of Tetrazole Derivatives and Their Antibacterial Activity
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Short Note

2-(2-(4-Methoxyphenyl)-4,9-dimethyl-7-oxo-7H-furo[2,3-f]chromen-3-yl)acetic Acid

by
Boris V. Lichitsky
,
Andrey N. Komogortsev
* and
Valeriya G. Melekhina
N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Science, Leninsky Pr., 47, 119991 Moscow, Russia
*
Author to whom correspondence should be addressed.
Molbank 2021, 2021(4), M1304; https://doi.org/10.3390/M1304
Submission received: 12 November 2021 / Revised: 30 November 2021 / Accepted: 6 December 2021 / Published: 9 December 2021
(This article belongs to the Section Organic Synthesis and Biosynthesis)

Abstract

:
For the first time, we describe a new approach towards the synthesis of previously unknown 2-(2-(4-methoxyphenyl)-4,9-dimethyl-7-oxo-7H-furo[2,3-f]chromen-3-yl)acetic acid. The presented method is based on the multicomponent condensation of 5-hydroxy-4,7-dimethyl-2H-chromen-2-one, 4-methoxyphenylglyoxal and Meldrum’s acid. It was shown that the studied reaction proceeds in two steps including the initial interaction of starting materials in MeCN and the final formation of furylacetic acid moiety in acidic media. The structures of the obtained compound were established by 1H, 13C-NMR spectroscopy and high-resolution mass spectrometry.

Graphical Abstract

1. Introduction

Furocoumarin derivatives are an important class of heterocyclic compounds widely presented in various natural products [1,2,3,4,5,6,7]. Numerous representatives of furocoumarins possess significant biological activity [8,9,10,11,12,13,14]. Generally, products of this type are used as active photosensitizers in psoralen and UVA (PUVA) therapy. Thus, furocoumarins can be employed in treatment of various skin diseases [15,16,17,18,19,20,21,22]. In this regard, the development of new methods for the synthesis of products containing the furocoumarin moiety is of considerable interest.
In most cases, furocoumarins can be prepared on the basis of substituted hydroxycoumarins. α-Halogen ketones are generally employed as the second component for the formation of the furocoumarin moiety [23,24,25,26,27,28]. Wherein, the use of the methodology of multicomponent reactions can open access to a wide range of products containing the furocoumarin fragment. A significant advantage of this approach is the ability to obtain target products in one synthetic stage [29,30,31,32,33]. It should be noted that we previously proposed a general approach to the synthesis of condensed furylacetic acids based on the multicomponent reaction of various hydroxyl derivatives with arylglyoxals and Meldrum’s acid [34,35,36,37,38]. We assumed that this approach could be used to synthesize substituted furo[2,3-f]coumarins.

2. Results

In the present communication, we report that a multicomponent reaction of 5-hydroxy-4,7-dimethyl-2H-chromen-2-one 1, 4-methoxyphenylglyoxal 2 and Meldrum’s acid 3 in the presence of Et3N leads to previously unknown 2-(2-(4-methoxyphenyl)-4,9-dimethyl-7-oxo-7H-furo[2,3-f]chromen-3-yl)acetic acid 4 (Scheme 1). Earlier, it was demonstrated that this type of reaction is a two-step cascade process. Herein, the interaction of components in acetonitrile (MeCN) proceeds at the first stage, and the final acid-catalyzed cyclization leads to the target product. It is important to note that in the considered case prolonged reflux (16 h) in MeCN is necessary for the synthesis of furocoumarin derivative 4. At the same time, it is necessary to use a 6-fold excess of arylglyoxal 2, Meldrum’s acid 3, and Et3N for the complete conversion of coumarin 1 to target product 4. It should be noted that the starting compound 1 remains as an impurity in the resulting product 2 if a smaller excess of the above-mentioned reagents is used. Apparently, this difference is due to the low reactivity of the coumarin 1 compared with those of the previously studied hydroxyl derivatives. Wherein, a mixture of hydrochloric and acetic acids is used for the final cyclization similar to the previous works [34,35,36,37,38]. The presented method allows one to synthesize the target 2-(2-(4-methoxyphenyl)-4,9-dimethyl-7-oxo-7H-furo[2,3-f]chromen-3-yl)acetic acid 4 with a 74% yield.
The proposed reaction mechanism is presented in Scheme 2. At the first step, interaction of Meldrum’s acid 3 with arylglyoxal 2 leads to intermediate A. Next, the addition of coumarin anion B to Michael acceptor A results in the formation of adduct D. The further acid-catalyzed cleavage of Meldrum’s acid moiety is followed by the elimination of CO2 and acetone-produced γ-ketoacid F. Finally, intermediate F is transformed to the target product 4 via cyclodehydration including the hydroxyl group of the coumarin fragment and the carbonyl unit.
In summary, a convenient one-pot cascade method for the synthesis of previously unknown 2-(2-(4-methoxyphenyl)-4,9-dimethyl-7-oxo-7H-furo[2,3-f]chromen-3-yl)acetic acid based on the multicomponent condensation of 5-hydroxy-4,7-dimethyl-2H-chromen-2-one, 4-methoxyphenylglyoxal and Meldrum’s acid was elaborated. The advantages of this approach are the application of readily available starting compounds, atom economy, and easy work-up procedures, which can avoid chromatographic purification. The structure of the synthesized furocoumarin was confirmed by 1H, 13C-NMR spectroscopy and high-resolution mass spectrometry.

3. Materials and Methods

All starting chemicals and solvents were commercially available and were used as received. NMR spectra were recorded with Bruker DRX 500 (500 MHz) spectrometers (Billerica, MA, USA) in DMSO-d6. Chemical shifts (ppm) were given relative to solvent signals (DMSO-d6: 2.50 ppm (1H NMR) and 39.52 ppm (13C NMR)). High-resolution mass spectra (HRMS) were obtained on a Bruker micrOTOF II instrument (Bruker Daltonik Gmbh, Bremen, Germany) using electrospray ionization (ESI). The melting points were determined on a Kofler hot stage (Dresden, Germany). IR spectra were recorded on a Bruker ALPHA (Santa Barbara, CA 93117, USA) spectrophotometer in a KBr pellet.

Experimental Procedure for the Synthesis of 2-(2-(4-methoxyphenyl)-4,9-dimethyl-7-oxo-7H-furo[2,3-f]chromen-3-yl)acetic Acid 4

A mixture of 5-hydroxy-4,7-dimethyl-2H-chromen-2-one 1 (2 mmol, 0.38 g), 4-methoxyphenylglyoxal hydrate 2 (6 mmol, 1.09 g), Meldrum’s acid 3 (6 mmol, 0.86 g), and Et3N (6 mmol, 0.84 mL) in 10 mL of MeCN was refluxed for 8 h. Then, an additional amount of 4-methoxyphenylglyoxal hydrate 2 (6 mmol, 1.09 g), Meldrum’s acid 3 (6 mmol, 0.86 g), and Et3N (6 mmol, 0.84 mL) was added, and the reaction mixture was refluxed for 8 h. Next, AcOH (5 mL) was added, and the solvent was evaporated under a reduced pressure. Then, AcOH (6 mL) and HClconc (3 mL) were added to the residue, and the solution was refluxed for 15 min. Further, the solution was cooled, and the resulting precipitate was filtered off and washed 70% aq. AcOH (3 × 7 mL). To remove traces of AcOH and HCl, the precipitate was kept for 24 h in water (50 mL) at room temperature, collected by filtration and washed with water (3 × 10 mL). Pale yellow powder; yield 74% (0.56 g, 1.5 mmol); Rf = 0.6 (ethyl acetate/methanol volume ratio = 4:1); mp 291–293 °C. 1H NMR (500 MHz, DMSO-d6) (Figure S1) δ 12.63 (br.s, 1H), 7.69 (d, J = 8.8 Hz, 2H), 7.13 (d, J = 8.8 Hz, 2H), 7.06 (d, J = 1.1 Hz, 1H), 6.30 (d, J = 1.5 Hz, 1H), 3.92 (s, 2H), 3.84 (s, 3H), 2.74 (d, J = 1.3 Hz, 3H), and 2.66 (s, 3H). 13C NMR (126 MHz, DMSO-d6) (Figure S2) δ 172.19, 159.71, 159.40, 152.90, 151.26, 150.77, 148.72, 135.41, 128.27, 124.51, 121.73, 114.45, 113.22, 113.16, 108.77, 104.39, 55.14, 30.69, 21.03, and 18.63. IR spectra (KBr) (Figure S4), ν, cm−1: 3061, 3000, 2957, 2837, 2684, 2595, 2554, 2422, 2061, 1904, 1836, 1726, 1694, 1670, 1626, 1511, 1453, 1401, 1384, 1365, 1308, 1256, 1215, 1177, 1159, 1110, 1065, 1035, 992, 924. HRMS (ESI-TOF) (Figure S3) m/z: [M+H]+ Calcld for C22H18O6: 379.1176; Found: 379.1177.

Supplementary Materials

The following are available online: copies of 1H, 13C-NMR, mass and IR spectra for compound 4. Figure S1: 1H NMR spectrum (500 MHz) of 4 in DMSO-d6; Figure S2: 13C {1H} NMR spectrum (126 MHz) of 4 in DMSO-d6; Figure S3: HRMS for compound 4; Figure S4: IR spectrum for compound 4.

Author Contributions

A.N.K. performed conceptualization, synthesis, spectroscopic analysis, and the writing of the manuscript. B.V.L. performed conceptualization, synthesis, spectroscopic analysis, and the writing of the manuscript. V.G.M. performed conceptualization, synthesis, spectroscopic analysis, and the writing of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

The data for the compounds presented in this study are available in Supplementary Materials of this article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Matos, M.J.; Santana, L.; Uriarte, E.; Abreu, O.A.; Molina, E.; Yordi, E.M.A.E.G. Coumarins—An Important Class of Phytochemicals. In Phytochemicals—Isolation, Characterisation and Role in Human Health; Rao, A.V., Rao, L.G., Eds.; IntechOpen: London, UK, 2015; pp. 113s–140s. [Google Scholar] [CrossRef] [Green Version]
  2. Venugopala, K.N.; Rashmi, V.; Odhav, B. Review on Natural Coumarin Lead Compounds for Their Pharmacological Activity. BioMed Res. Int. 2013, 2013, 1–14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Bordin, F.; Dall’Acqua, F.; Guiotto, A. Angelicins, angular analogs of psoralens: Chemistry, photochemical, photobiological and phototherapeutic properties. Pharmacol. Ther. 1991, 52, 331–363. [Google Scholar] [CrossRef]
  4. Chaudhary, S.K.; Ceska, O.; Warrington, P.J.; Ashwood-Smith, M.J. Increased furocoumarin content of celery during storage. J. Agric. Food Chem. 1985, 33, 1153–1157. [Google Scholar] [CrossRef]
  5. Chen, C.-H.; Hwang, T.-L.; Chen, L.-C.; Chang, T.-H.; Wei, C.-S.; Chen, J.-J. Isoflavones and anti-inflammatory constituents from the fruits of Psoralea corylifolia. Phytochemistry 2017, 143, 186–193. [Google Scholar] [CrossRef]
  6. Dugrand-Judek, A.; Olry, A.; Hehn, A.; Costantino, G.; Ollitrault, P.; Froelicher, Y.; Bourgaud, F. The Distribution of Coumarins and Furanocoumarins in Citrus Species Closely Matches Citrus Phylogeny and Reflects the Organization of Biosynthetic Pathways. PLoS ONE 2015, 10, e0142757. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Melough, M.M.; Cho, E.; Chun, O.K. Furocoumarins: A review of biochemical activities, dietary sources and intake, and potential health risks. Food Chem. Toxicol. 2018, 113, 99–107. [Google Scholar] [CrossRef] [PubMed]
  8. Hadaček, F.; Müller, C.; Werner, A.; Greger, H.; Proksch, P. Analysis, isolation and insecticidal activity of linear furanocoumarins and other coumarin derivatives fromPeucedanum (Apiaceae: Apioideae). J. Chem. Ecol. 1994, 20, 2035–2054. [Google Scholar] [CrossRef] [PubMed]
  9. Wangchuk, P.; Pyne, S.; Keller, P.; Taweechotipatr, M.; Kamchonwongpaisan, S. Phenylpropanoids and Furanocoumarins as Antibacterial and Antimalarial Constituents of the Bhutanese Medicinal Plant Pleurospermum amabile. Nat. Prod. Commun. 2014, 9, 1934578X1400900719. [Google Scholar] [CrossRef] [Green Version]
  10. Souri, E.; Farsam, H.; Sarkheil, P.; Ebadi, F. Antioxidant Activity of Some Furanocoumarins Isolated fromHeracleum persicum. Pharm. Biol. 2004, 42, 396–399. [Google Scholar] [CrossRef] [Green Version]
  11. Hung, W.-L.; Suh, J.H.; Wang, Y. Chemistry and health effects of furanocoumarins in grapefruit. J. Food Drug Anal. 2016, 25, 71–83. [Google Scholar] [CrossRef] [Green Version]
  12. Bruni, R.; Barreca, D.; Protti, M.; Brighenti, V.; Righetti, L.; Anceschi, L.; Mercolini, L.; Benvenuti, S.; Gattuso, G.; Pellati, F. Botanical Sources, Chemistry, Analysis, and Biological Activity of Furanocoumarins of Pharmaceutical Interest. Molecules 2019, 24, 2163. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Dongfack, M.D.J.; Lallemand, M.-C.; Kuete, V.; Mbazoa, C.D.; Wansi, J.-D.; Trinh-Van-Dufat, H.; Michel, S.; Wandji, J. A New Sphingolipid and Furanocoumarins with Antimicrobial Activity from Ficus exasperata. Chem. Pharm. Bull. 2012, 60, 1072–1075. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Li, W.; Schuler, M.A.; Berenbaum, M.R. Diversification of furanocoumarin-metabolizing cytochrome P450 monooxygenases in two papilionids: Specificity and substrate encounter rate. Proc. Natl. Acad. Sci. USA 2003, 100 (Suppl. S2), 14593–14598. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Niu, C.; Lu, X.; Aisa, H.A. Preparation of novel 1,2,3-triazole furocoumarin derivatives via click chemistry and their anti-vitiligo activity. RSC Adv. 2019, 9, 1671–1678. [Google Scholar] [CrossRef] [Green Version]
  16. Niu, C.; Yin, L.; Aisa, H.A. Novel Furocoumarin Derivatives Stimulate Melanogenesis in B16 Melanoma Cells by Up-Regulation of MITF and TYR Family via Akt/GSK3β/β-Catenin Signaling Pathways. Int. J. Mol. Sci. 2018, 19, 746. [Google Scholar] [CrossRef] [Green Version]
  17. Gupta, A.K.; Anderson, T.F. Psoralen photochemotherapy. J. Am. Acad. Dermatol. 1987, 17, 703–734. [Google Scholar] [CrossRef]
  18. Honig, B.; Morison, W.L.; Karp, D. Photochemotherapy beyond psoriasis. J. Am. Acad. Dermatol. 1994, 31, 775–790. [Google Scholar] [CrossRef]
  19. Khurshid, K.; Haroon, T.S.; Hussain, I.; Pal, S.S.; Jahangir, M.; Zaman, T. Psoralen-ultraviolet A therapy vs. psoralen-ultraviolet B therapy in the treatment of plaque-type psoriasis: Our experience with fitzpatrick skin type IV. Int. J. Dermatol. 2000, 39, 865–867. [Google Scholar] [CrossRef] [PubMed]
  20. Wolf, P. Psoralen–ultraviolet A endures as one of the most powerful treatments in dermatology: Reinforcement of this ‘triple-product therapy’ by the 2016 British guidelines. Br. J. Dermatol. 2016, 174, 11–14. [Google Scholar] [CrossRef] [PubMed]
  21. Farahnik, B.; Nakamura, M.; Singh, R.K.; Abrouk, M.; Zhu, T.H.; Lee, K.M.; Jose, M.V.; Dalovisio, R.; Koo, J.; Bhutani, T.; et al. The Patient’s Guide to Psoriasis Treatment. Part 2: PUVA Phototherapy. Dermatol. Ther. 2016, 6, 315–324. [Google Scholar] [CrossRef] [Green Version]
  22. Vasquez, R.; Jacobe, H. Phototherapy for sclerosing skin conditions. Expert Rev. Dermatol. 2011, 6, 595–612. [Google Scholar] [CrossRef] [Green Version]
  23. Traven, V.F. New Synthetic Routes to Furocoumarins and Their Analogs: A Review. Molecules 2004, 9, 50–66. [Google Scholar] [CrossRef] [Green Version]
  24. El-Gogary, S.; Hashem, N.; Khodeir, M.N. Synthesis and photooxygenation of angular furocoumarins: Isopsedopsoralen and allopsoralen. Res. Chem. Intermed. 2013, 41, 1591–1600. [Google Scholar] [CrossRef]
  25. Via, L.D.; Mammi, S.; Uriarte, E.; Santana, L.; Lampronti, I.; Gambari, A.R.; Gia, O. New Furan Side Tetracyclic Allopsoralen Derivatives: Synthesis and Photobiological Evaluation. J. Med. Chem. 2006, 49, 4317–4326. [Google Scholar] [CrossRef]
  26. Uriarte, E.; González-Gómez, J.C.; Santana, L. Regioselective Synthesis of Linear and Angular Pyridazine Furocoumarins. Synthesis 2002, 2002, 0043–0046. [Google Scholar] [CrossRef]
  27. Jamalis, J.; Yusof, F.S.M.; Chander, S.; Wahab, R.A.; Bhagwat, D.P.; Sankaranarayanan, M.; Almalki, F.; Ben Hadda, T. Psoralen Derivatives: Recent Advances of Synthetic Strategy and Pharmacological Properties. Anti-Inflamm. Anti-Allergy Agents Med. Chem. 2020, 19, 222–239. [Google Scholar] [CrossRef]
  28. Garazd, M.M.; Garazd, Y.L.; Shilin, S.V.; Khilya, V.P. Modified Coumarins. I. Synthesis of 5-Phenyl-7H-furo[2, 3-g]chromen-7-ones and 9-Phenyl-7H-furo-[2, 3-f]chromen-7-ones. Chem. Nat. Compd. 2000, 36, 478–484. [Google Scholar] [CrossRef]
  29. Touré, B.B.; Hall, D. Natural Product Synthesis Using Multicomponent Reaction Strategies. Chem. Rev. 2009, 109, 4439–4486. [Google Scholar] [CrossRef]
  30. Ulaczyk-Lesanko, A.; Hall, D.G. Wanted: New multicomponent reactions for generating libraries of polycyclic natural products. Curr. Opin. Chem. Biol. 2005, 9, 266–276. [Google Scholar] [CrossRef] [PubMed]
  31. Dömling, A.; Wang, W.; Wang, K. Chemistry and Biology Of Multicomponent Reactions. Chem. Rev. 2012, 112, 3083–3135. [Google Scholar] [CrossRef] [Green Version]
  32. John, S.E.; Gulati, S.; Shankaraiah, N. Recent advances in multi-component reactions and their mechanistic insights: A triennium review. Org. Chem. Front. 2021, 8, 4237–4287. [Google Scholar] [CrossRef]
  33. Younus, H.A.; Al-Rashida, M.; Hameed, A.; Uroos, M.; Salar, U.; Rana, S.; Khan, K.M. Multicomponent reactions (MCR) in medicinal chemistry: A patent review (2010–2020). Expert Opin. Ther. Patents 2021, 31, 267–289. [Google Scholar] [CrossRef] [PubMed]
  34. Komogortsev, A.N.; Lichitsky, B.V.; Melekhina, V.G. Straightforward One-Step Approach towards Novel Derivatives of 9-Oxo-5,6,7,9-Tetrahydrobenzo[9,10]Heptaleno[3,2-b]Furan-12-yl)Acetic Acid Based on the Multicomponent Reaction of Colchiceine, Arylglyoxals and Meldrum’s Acid. Tetrahedron Lett. 2021, 78, 153292. [Google Scholar] [CrossRef]
  35. Gorbunov, Y.O.; Lichitsky, B.V.; Komogortsev, A.N.; Mityanov, V.S.; Dudinov, A.A.; Krayushkin, M.M. Synthesis of Condensed Furylacetic Acids Based on Multicomponent Condensation of Heterocyclic Enols with Arylglyoxals and Meldrum’s Acid. Chem. Heterocycl. Compd. 2018, 54, 692–695. [Google Scholar] [CrossRef]
  36. Komogortsev, A.N.; Lichitsky, B.V.; Tretyakov, A.D.; Dudinov, A.A.; Krayushkin, M.M. Investigation of the multicomponent reaction of 5-hydroxy-2-methyl-4H-pyran-4-one with carbonyl compounds and Meldrum’s acid. Chem. Heterocycl. Compd. 2019, 55, 818–822. [Google Scholar] [CrossRef]
  37. Lichitsky, B.V.; Melekhina, V.G.; Komogortsev, A.N.; Minyaev, M.E. A new multicomponent approach to the synthesis of substituted furan-2(5H)-ones containing 4H-chromen-4-one fragment. Tetrahedron Lett. 2020, 61, 152602. [Google Scholar] [CrossRef]
  38. Lichitsky, B.V.; Tretyakov, A.D.; Komogortsev, A.N.; Mityanov, V.; Dudinov, A.A.; Gorbunov, Y.O.; Daeva, E.D.; Krayushkin, M.M. Synthesis of substituted benzofuran-3-ylacetic acids based on three-component condensation of polyalkoxyphenols, arylglyoxals and Meldrum’s acid. Mendeleev Commun. 2019, 29, 587–588. [Google Scholar] [CrossRef]
Scheme 1. Synthesis of 2-(2-(4-methoxyphenyl)-4,9-dimethyl-7-oxo-7H-furo[2,3-f]chromen-3-yl)acetic acid 4.
Scheme 1. Synthesis of 2-(2-(4-methoxyphenyl)-4,9-dimethyl-7-oxo-7H-furo[2,3-f]chromen-3-yl)acetic acid 4.
Molbank 2021 m1304 sch001
Scheme 2. Proposed reaction mechanism for the formation of 2-(2-(4-methoxyphenyl)-4,9-dimethyl-7-oxo-7H-furo[2,3-f]chromen-3-yl)acetic acid 4.
Scheme 2. Proposed reaction mechanism for the formation of 2-(2-(4-methoxyphenyl)-4,9-dimethyl-7-oxo-7H-furo[2,3-f]chromen-3-yl)acetic acid 4.
Molbank 2021 m1304 sch002
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Lichitsky, B.V.; Komogortsev, A.N.; Melekhina, V.G. 2-(2-(4-Methoxyphenyl)-4,9-dimethyl-7-oxo-7H-furo[2,3-f]chromen-3-yl)acetic Acid. Molbank 2021, 2021, M1304. https://doi.org/10.3390/M1304

AMA Style

Lichitsky BV, Komogortsev AN, Melekhina VG. 2-(2-(4-Methoxyphenyl)-4,9-dimethyl-7-oxo-7H-furo[2,3-f]chromen-3-yl)acetic Acid. Molbank. 2021; 2021(4):M1304. https://doi.org/10.3390/M1304

Chicago/Turabian Style

Lichitsky, Boris V., Andrey N. Komogortsev, and Valeriya G. Melekhina. 2021. "2-(2-(4-Methoxyphenyl)-4,9-dimethyl-7-oxo-7H-furo[2,3-f]chromen-3-yl)acetic Acid" Molbank 2021, no. 4: M1304. https://doi.org/10.3390/M1304

APA Style

Lichitsky, B. V., Komogortsev, A. N., & Melekhina, V. G. (2021). 2-(2-(4-Methoxyphenyl)-4,9-dimethyl-7-oxo-7H-furo[2,3-f]chromen-3-yl)acetic Acid. Molbank, 2021(4), M1304. https://doi.org/10.3390/M1304

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop